These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 2585020)

  • 41. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
    Hagenbeek A; Carde P; Meerwaldt JH; Somers R; Thomas J; De Bock R; Raemaekers JM; van Hoof A; De Wolf-Peeters C; van Glabbeke M
    J Clin Oncol; 1998 Jan; 16(1):41-7. PubMed ID: 9440721
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diffuse aggressive lymphoma.
    Fisher RI; Miller TP; O'Connor OA
    Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pleural effusion in patients with non-Hodgkin's lymphoma: a case-controlled study.
    Elis A; Blickstein D; Mulchanov I; Manor Y; Radnay J; Shapiro H; Lishner M
    Cancer; 1998 Oct; 83(8):1607-11. PubMed ID: 9781955
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ki-1 antigen expression defines a favorable clinical subset of non-B cell non-Hodgkin's lymphoma.
    Offit K; Ladanyi M; Gangi MD; Ebrahim SA; Filippa D; Chaganti RS
    Leukemia; 1990 Sep; 4(9):625-30. PubMed ID: 2168505
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
    Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
    Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
    Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.
    Martelli M; Gherlinzoni F; De Renzo A; Zinzani PL; De Vivo A; Cantonetti M; Falini B; Storti S; Meloni G; Rizzo M; Molinari AL; Lauria F; Moretti L; Lauta VM; Mazza P; Guardigni L; Pescarmona E; Pileri SA; Mandelli F; Tura S
    J Clin Oncol; 2003 Apr; 21(7):1255-62. PubMed ID: 12663712
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
    Qin Y; Shi YK; He XH; Yang JL; Yang S; Yu YX; Li B; Wang QL; Zhou LQ; Sun Y
    Ai Zheng; 2006 Apr; 25(4):481-5. PubMed ID: 16613685
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
    Sonneveld P; de Ridder M; van der Lelie H; Nieuwenhuis K; Schouten H; Mulder A; van Reijswoud I; Hop W; Lowenberg B
    J Clin Oncol; 1995 Oct; 13(10):2530-9. PubMed ID: 7595704
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Mounier N; Gisselbrecht C; Brière J; Haioun C; Feugier P; Offner F; Recher C; Stamatoullas A; Morschhauser F; Macro M; Thieblemont C; Sonet A; Fabiani B; Reyes F;
    J Clin Oncol; 2004 Jul; 22(14):2826-34. PubMed ID: 15254050
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis.
    Gómez H; Hidalgo M; Casanova L; Colomer R; Pen DL; Otero J; Rodríguez W; Carracedo C; Cortés-Funes H; Vallejos C
    J Clin Oncol; 1998 Jun; 16(6):2065-9. PubMed ID: 9626205
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 53. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
    Santini G; Coser P; Congiu AM; Salvagno L; De Souza C; Sertoli MR; Olivieri A; Chisesi T; Rubagotti A; Truini M; Contu A; Porcellini A; Zambaldi G; Nati S; Marino G; Rizzoli V
    Haematologica; 2000 Feb; 85(2):160-6. PubMed ID: 10681723
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Importance of cell surface marker to the prognosis of non-Hodgkin's lymphoma.
    Toki H; Okabe K; Kamei H; Segawa Y; Koike S
    Acta Med Okayama; 1988 Oct; 42(5):287-92. PubMed ID: 3265575
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The pathologic and clinical heterogeneity of lymphocyte-depleted Hodgkin's disease.
    Kant JA; Hubbard SM; Longo DL; Simon RM; DeVita VT; Jaffe ES
    J Clin Oncol; 1986 Mar; 4(3):284-94. PubMed ID: 3754003
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades--should peripheral T-cell lymphoma be considered separately?
    Cheng AL; Chen YC; Wang CH; Su IJ; Hsieh HC; Chang JY; Hwang WS; Su WC; Liu TW; Tien HF
    J Clin Oncol; 1989 Jun; 7(6):725-31. PubMed ID: 2654330
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diffuse small cleaved-cell lymphoma: a heterogeneous disease with distinct immunobiologic subsets.
    Leith CP; Spier CM; Grogan TM; Gonzales G; Rangel CS; Rybski JA; Matzner M; Miller TP
    J Clin Oncol; 1992 Aug; 10(8):1259-65. PubMed ID: 1634915
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Ki-1 non-Hodgkin's lymphoma. A multihospital study of 21 cases].
    Rivas C; Obeso G; Piris M; Castrillo JM; Bellas C; Acevedo A; Martín C; Campo E; Gamallo C; Font M
    Rev Clin Esp; 1989 Mar; 184(5):238-44. PubMed ID: 2549584
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA).
    Gisselbrecht C; Gaulard P; Lepage E; Coiffier B; Brière J; Haioun C; Cazals-Hatem D; Bosly A; Xerri L; Tilly H; Berger F; Bouhabdallah R; Diebold J
    Blood; 1998 Jul; 92(1):76-82. PubMed ID: 9639502
    [TBL] [Abstract][Full Text] [Related]  

  • 60. t(9;14)(p13;q32) denotes a subset of low-grade non-Hodgkin's lymphoma with plasmacytoid differentiation.
    Offit K; Parsa NZ; Filippa D; Jhanwar SC; Chaganti RS
    Blood; 1992 Nov; 80(10):2594-9. PubMed ID: 1384792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.